High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations.
Zhuoer Xie, Jenna Fernandez, Terra Lasho...
https://pubmed.ncbi.nlm.nih.gov/39352751/Actively Recruiting
Led by Mayo Clinic · Updated on 2026-09-28
80
Participants Needed
4
Research Sites
140 weeks
Total Duration
This trial evaluates the effects of high dose intravenous ascorbic acid combined with chemotherapy in patients with relapsed or refractory lymphoma, clonal cytopenia of undetermined significance CCUS, and chronic myelomonocytic leukemia CMML. The study aims to determine response rates and safety of adding ascorbic acid to standard treatments for these blood cancers and related conditions. It also investigates biological markers related to treatment effects and disease progression. Participants receive ascorbic acid intravenously along with various chemotherapy regimens depending on their disease type and study arm. Some arms involve combination chemotherapy with drugs like rituximab, ifosfamide, carboplatin, etoposide, and others, while some focus on ascorbic acid with decitabine or other agents. Treatments are given in cycles, ranging from every 21 days up to 12 cycles or longer, depending on response and tolerance. Some study arms are closed for enrollment, while others remain active. During the study, participants undergo blood tests, bone marrow biopsies, imaging scans such as PETCT or MRI, and heart function tests. Central lines like PICC or portacath may be placed for treatment delivery. Researchers monitor response rates, survival, adverse events, symptom changes, and biological markers throughout treatment and follow-up. After treatment, participants are followed every 3 to 6 months for up to two years to assess long-term outcomes and safety.
CONDITIONS
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
C
Clinical Trials Referral Office
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Mayo Clinic
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | High-dose ascorbic acid (IV) with combination chemotherapy | Placebo (IV saline) with combination chemotherapy | Ascorbic acid alone or with decitabine (by trial arm/eligibility) |
|---|---|---|---|
| What it is | High-dose intravenous ascorbic acid given with a combination of chemotherapy drugs, including platinum-based regimens, with or without rituximab depending on lymphoma type. | Placebo (intravenous saline) given alongside the same chemotherapy combination regimens as the investigational arm. | High-dose intravenous ascorbic acid, either given alone or with decitabine or decitabine/cedazuridine, depending on assigned arm and disease (CCUS, CMML). |
| Role in the trial | Primary investigational arm testing whether ascorbic acid enhances chemotherapy effectiveness in relapsed or refractory lymphomas. | Active control arm using identical chemotherapy plus intravenous placebo, allowing direct comparison to investigational ascorbic acid effect. | Exploratory investigational arms for hematologic neoplasms (CCUS with TET2 or other mutations, CMML), evaluating ascorbic acid with or without epigenetic treatment. |
| Primary use or intent | Evaluates efficacy and safety of adding ascorbic acid to combination chemotherapy for relapsed or refractory lymphoma. | Provides a comparator to measure the added value, if any, of ascorbic acid when all other treatments are the same. | Assesses activity of ascorbic acid, alone or with hypomethylating agents, in patients with CCUS (with TET2 or related mutations) or CMML needing treatment. |
| How it is given or performed | Ascorbic acid is administered intravenously with platinum-based chemotherapy regimens, with or without rituximab, per the assigned arm. Protocol includes use of ifosfamide/carboplatin/etoposide (ICE), DHAP, GDP, GemOx, OAD, and related combinations. | Placebo is administered as intravenous saline alongside the same platinum-based chemotherapy regimens as the investigational arm. | Ascorbic acid is given intravenously alone or with decitabine or oral decitabine/cedazuridine in participants with specific hematologic mutations, according to registry protocol assignment. |
| Evidence status | Effectiveness of adding high-dose ascorbic acid to platinum-based chemotherapy in relapsed or refractory lymphoma is under investigation; no published phase 2+ randomized outcome results are yet available. | Platinum-based chemotherapy regimens are established salvage therapies with published response rates in relapsed/refractory lymphoma, but prognosis remains guarded after relapse. | For CCUS with TET2 mutations, early data from recent phase 1/2 studies support biological activity of high-dose IV ascorbic acid, but clinical benefit remains investigational. |
| Important limitations | The added value, safety profile, and long-term outcomes of ascorbic acid when combined with chemotherapy for lymphoma are not yet established and remain experimental within this trial. | Although standard platinum-based salvage chemotherapy regimens are established, many patients relapse, and durable remission rates after second-line therapy remain low. | Clinical benefit and long-term safety of high-dose ascorbic acid, alone or with hypomethylating agents, in CCUS or CMML remain unproven and are still under exploratory investigation. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 12 cycles (varies by arm)
Participants receive intravenous ascorbic acid combined with chemotherapy or related therapies according to their assigned study group.
Regular visits for treatment and monitoring during cycles
Duration - Up to 2 years
After completing treatment, participants are followed up every 3 months, then every 6 months after disease progression for up to 2 years to assess long-term outcomes and safety.
Follow-up visits every 3 to 6 months
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
5
Have more questions? Get in touch with our team for quick support
Zhuoer Xie, Jenna Fernandez, Terra Lasho...
https://pubmed.ncbi.nlm.nih.gov/39352751/Mayo Clinic
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor